Antitumor efficacy and molecular mechanism of TLK58747, a novel DNA-alkylating prodrug

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 3845-3855

  Xu, Hua ^a   Wang, Zhuo ^a   Donaldson, John C ^a   Yao, Hong ^a   Zhou, Siqun ^a   Kelson, Andrew B ^a   Ma, Wenli ^a   Weber, Kevin T ^a   Laborde, Edgardo ^a   Cheng, Mingshan ^a   Sambucetti, Lidia ^a   Keck, James G ^a  

^a Telik Inc   (United States)

Author keywords

Alkylator; Bone marrow sparing; Cell cycle arrest; DNA damage; Drug resistance; Prodrug

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CASPASE 3; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PACLITAXEL; TLK 58747; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BEHAVIOR CHANGE; BODY WEIGHT; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DNA ALKYLATION; DNA DAMAGE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; LEUKEMIA; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RAT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL DIVISION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA DAMAGE; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HL-60 CELLS; HUMANS; MALE; MICE; NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71949108287     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kimby E, Brandt L, Nygren P and Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia. Acta Oncol 40: 224-230, 2001.
2. Keating MJ, Bach C, Yasothan U and Kirkpatrick P: Bendamustine. Nat Rev Drug Discov 7: 473-474, 2008.
3. Rodeghiero F and Elice F: Ifosfamide in hematological malignancies of adults. Oncology 65(Suppl 2): 85-93, 2003.
4. Lin SH and Kleinberg LR: Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8: 343-359, 2008.
5. Chabner BA and Roberts TG Jr: Chemotherapy and the war on cancer. Nature Reviews Cancer 5: 65-72, 2005.
6. Bergmann MA: Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 90: 1357-1364, 2005.
7. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G and Niemeyer CC: Bendamustine (Treanda®) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14: 309-317, 2008.
8. Knauf W: Bendamustine in the treatment of chronic lymphocytic leukemia. Expert Rev Anticancer Ther 9: 165-174, 2009.
9. Kavanagh JJ, Gershenson DM, Choi H, Lewis L, Patel K, Brown GL, Garcia A and Spriggs DR: Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione-S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer 15: 593-600, 2005. (Pubitemid 41022895)
10. Jain M, Fan J, Baturay NZ and Kwon CH: Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines. Med Chem 47: 3843-3852, 2004. (Pubitemid 38900349)
11. Lyttle MH, Satyam A, Hocker MD, Bauer KE, Caldwell CG, Hui HC, Morgan AS, Mergia A and Kauvar LM: Glutathione-S-transferase activates novel alkylating agents. J Med Chem 37: 1501-1507, 1994. (Pubitemid 24174088)
12. Hayes JD and Pulford DJ: The glutathione-S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30(6): 445-600, 1995. (Pubitemid 26016466)
13. O'Brien ML and Tew KD: Glutathione and related enzymes in multidrug resistance. Eur J Cancer 32A(6): 967-978, 1996. (Pubitemid 26191764)
14. Rosen LS, Laxa B, Boulos L, Wiggins L, Keck JG, Jameson AJ, Parra R, Patel K and Brown GL: Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies. Clin Cancer Res 10: 3689-3698, 2004. (Pubitemid 38697602)
15. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M and Campisi J: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367, 1995.
16. Shen D, Pastan I and Gottesman MM: Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 58: 268-275, 1998. (Pubitemid 28047066)
17. 14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 183: 108-116, 2000. (Pubitemid 30130231)
18. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002. (Pubitemid 37328807)
19. Fojo T and Coley HM: The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies. Clin Breast Cancer 7: 749-756, 2007. (Pubitemid 350086119)
20. Johnson RK, Chitnis MP, Embrey WM and Gregory EB: In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 62: 1535-1547, 1978.
21. Seneviratne C and Goldenberg GJ: Further characterization of drug-sensitivity and cross-resistance profiles of cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Commun 1: 21-27, 1989.
22. Previati M, Lanzoni I, Corbacella E, Magosso S, Guaran V, Martini A and Capitani S: Cisplatin-induced apoptosis in human promyelocytic leukemia cells. Int J Mol Med 18: 511-516, 2006.
23. Masquelier M, Lundberg B, Peterson C and Vitols S: Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: studies in human leukemic cells. Leuk Res 30: 136-144, 2006. (Pubitemid 41773334)
24. Hurley LH: DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2: 188-200, 2002.
25. Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104, 1999.
26. Soldani C and Scovassi AI: Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7: 321-328, 2002. (Pubitemid 34832256)
27. 1 during growth arrest. Exp Cell Res 241: 324-331, 1998. (Pubitemid 28366558)
28. Vousden KH: Outcomes of p53 activation - spoilt for choice. J Cell Sci 119: 5015-5020, 2006.
29. 2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18: 629-643, 1998. (Pubitemid 28021073)
30. 2 arrest in human cells. J Cell Biol 134: 963-970, 1996. (Pubitemid 26278221)
31. Blasina A, Paegle ES and McGowan CH: The role of inhibitory phosphorylation of CDC2 following DNA replication block and radiation-induced damage in human cells. Mol Biol Cell 8: 1013-1023, 1997. (Pubitemid 27276322)
32. Wang JY and Ki SW: Choosing between growth arrest and apoptosis through the retinoblastoma tumour suppressor protein, Abl and p73. Biochem Soc Trans 29: 666-673, 2001.
33. Friberg LE, Henningsson A, Maas H, Nguyen L and Karlsson MO: Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20: 4713-4721, 2002. (Pubitemid 36025290)
34. Korkmaz A, Topal T and Oter S: Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol 23: 303-312, 2007.
35. Morgan AS, Sanderson PE, Borch RF, Tew KD, Niitsu Y, Takayama T, Von Hoff DD, Izbicka E, Mangold G, Paul C, Broberg U, Mannervik B, Henner WD and Kauvar LM: Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione-S-transferase. Cancer Res 58: 2568-2575, 1998. (Pubitemid 28275427)
36. Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW and Cheson BD: Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26: 204-210, 2008. Erratum in: J Clin Oncol 26: 1911, 2008.
37. Mann GJ, Maiden LT, Solomon HJ and Tattersall MH: Combined cyclophosphamide, adriamycin and cis-platinum in advanced ovarian cancer resistant to chlorambucil and cis-platinum. Gynecol Oncol 21: 215-219, 1985.
38. Hallek M and Eichhorst BF: Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. Hematol J 5(Suppl 1): S20-30, 2004.
39. Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N, Frankel SR, Kossman SE and Horgan D: Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 21: 1278-1284, 2003. (Pubitemid 46606404)
40. Fernandez-Capetillo O, Lee A, Nussenzweig M and Nussenzweig A: H2AX: the histone guardian of the genome: DNA Repair (Amst) 3: 959-967, 2004.
41. Gatei M, Sloper K, Sorensen C, Syljuäsen R, Falck J, Hobson K, Savage K, Lukas J, Zhou BB, Bartek J and Khanna KK: Ataxia-telangiectasia- mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 278: 14806-14811, 2003. (Pubitemid 36799806)
42. Bertheau P, Espié M, Turpin E, Lehmann J, Plassa LF, Varna M, Janin A and de The H: TP53 status and response to chemotherapy in breast cancer. Pathobiology 75: 132-139, 2008. (Pubitemid 351820731)
43. 2/M transition by p53. Oncogene 20: 1803-1815, 2001.